Instead, the overall survival data slightly favored the doublet. Patients who received the Cabometyx-containing triplet lived a median 41.9 months, versus 42 months for Opdivo-Yervoy alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback